Chronic Myeloid Leukemia Coverage from Every Angle
Advertisement
Advertisement

Jerald P. Radich, MD, on Clinical Implications of a Potential New Tool to Predict Treatment Response in CML

Posted: Wednesday, December 11, 2019

Jerald P. Radich, MD, of the Fred Hutchinson Cancer Research Center, discusses the possible courses of action a clinician may take based on whether a gene-expression model predicts that a patient’s chronic myeloid leukemia can respond to treatment with a tyrosine kinase inhibitor.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.